Skip to main content
GALT
NASDAQ Life Sciences

Chairman Converts $105.8M Debt to Equity, Eliminating Nearly All Debt

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.21
Mkt Cap
$199.546M
52W Low
$2.025
52W High
$7.13
52W Position info
59% above low
Off High info
55% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GALT sits 59% above its 52-week low of $2.025.

Summary

Chairman Richard Uihlein converted $105.8 million in debt to equity, eliminating nearly all of Galectin's debt and issuing 34.4 million shares at a blended average of $3.07 per share. The conversion covers five credit facilities, leaving only a $10 million undrawn facility. This follows the 8-K filed earlier today and the recent positive FDA feedback on belapectin's Phase 3 trial design. The balance sheet is now significantly strengthened, removing a major overhang and demonstrating the chairman's conviction. With 100.8 million shares outstanding post-conversion, the company is better positioned to advance belapectin toward a pivotal trial.

At the time of this announcement, GALT was trading at $3.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.5M. The 52-week trading range was $2.03 to $7.13. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.83 info
Change: -$0.270 (-9%) info
Market Cap: $285.477M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $2.83 info
Change: -$0.270 (-9%) info
Market Cap: $285.477M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.83 info
Change: -$1.11 (-28%) info
Market Cap: $285.477M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $2.83 info
Change: -$1.09 (-28%) info
Market Cap: $285.477M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.83 info
Change: -$0.620 (-18%) info
Market Cap: $285.477M info